BDWM
SPRO icon

Brewin Dolphin Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-600
Closed -$10K – 385
2021
Q4 		$10K Hold
600
– – ﹤0.01% 286
2021
Q3 		$11K Hold
600
– – ﹤0.01% 293
2021
Q2 		$8.38K Hold
600
– – ﹤0.01% 302
2021
Q1 		$8.83K Hold
600
– – ﹤0.01% 287
2020
Q4 		$11.6K Hold
600
– – ﹤0.01% 242
2020
Q3 		$6.7K Buy
+600
New +$7.1K ﹤0.01% 247

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Brewin Dolphin Wealth Management's SPRO Position: Q1 2022 in Review

Brewin Dolphin Wealth Management sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 600 shares — an estimated $10K sold.

Brewin Dolphin Wealth Management first reported a position in SPRO in Q3 2020 and held it in 6 quarters. The position peaked at $11.6K in Q4 2020. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • Brewin Dolphin Wealth Management reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 600 Spero Therapeutics shares in Q1 2022, an estimated $10K.
  • Brewin Dolphin Wealth Management first reported a position in Spero Therapeutics in Q3 2020 and held it in 6 quarters.
  • Brewin Dolphin Wealth Management's Spero Therapeutics position peaked at $11.6K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q1 2022, filed 14 Nov 2022.